Last updated: February 19, 2026
Daprodustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, is under development for the treatment of anemia associated with chronic kidney disease (CKD). This analysis reviews its current clinical trial status, examines market dynamics, and projects future performance.
What is the Current Status of Daprodustat's Clinical Development?
Daprodustat has advanced through extensive clinical trials across multiple phases, demonstrating efficacy and safety profiles for treating anemia in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) CKD patients. Key trial programs include:
-
AstraZeneca's ASCERTAIN Program: This global Phase III program comprised multiple studies evaluating daprodustat in NDD-CKD and DD-CKD patients. The program focused on efficacy and safety, particularly cardiovascular outcomes.
- ASCERTAIN-1 (NDD-CKD): Demonstrated non-inferiority of daprodustat compared to darbepoetin alfa in achieving and maintaining hemoglobin levels. Key cardiovascular safety endpoints were also assessed [1].
- ASCERTAIN-2 (DD-CKD): Showed non-inferiority of daprodustat to epoetin alfa for hemoglobin control and assessed cardiovascular safety in a dialysis population [2].
- ASCERTAIN-3 (Switching from ESAs): Evaluated the safety and efficacy of switching patients from erythropoiesis-stimulating agents (ESAs) to daprodustat in NDD-CKD and DD-CKD populations [3].
-
Global Registration Trials: These trials formed the basis for regulatory submissions. They consistently demonstrated daprodustat's ability to effectively raise and maintain hemoglobin levels, offering a convenient oral alternative to injectable ESAs [4].
-
Post-Marketing Surveillance and Real-World Evidence: Ongoing studies and analyses are gathering real-world data to further define daprodustat's long-term safety and effectiveness in diverse patient populations and across different healthcare systems [5].
Table 1: Key Daprodustat Clinical Trial Outcomes Summary
| Trial Name |
Patient Population |
Comparator(s) |
Primary Endpoint Achievement |
Key Safety Findings |
Regulatory Status |
| ASCERTAIN-1 |
NDD-CKD |
Darbepoetin alfa |
Achieved hemoglobin targets; Non-inferior efficacy |
MACE (Major Adverse Cardiovascular Events) rates comparable between groups; specific safety signals managed through dosing. |
Submitted for regulatory review in multiple regions. |
| ASCERTAIN-2 |
DD-CKD |
Epoetin alfa |
Achieved hemoglobin targets; Non-inferior efficacy |
MACE rates comparable between groups; manageable safety profile in dialysis patients. |
Submitted for regulatory review in multiple regions. |
| ASCERTAIN-3 |
NDD & DD-CKD (Switching) |
Continued ESA therapy (as control) |
Demonstrated efficacy and safety post-switch |
Generally well-tolerated following the switch; no new significant safety concerns identified. |
Data supports label expansion for switching indications. |
| Global Registration Trials |
NDD & DD-CKD |
ESAs (e.g., Darbepoetin alfa, Epoetin alfa) |
Consistent hemoglobin control, dose adjustments |
Cardiovascular safety profile considered acceptable, comparable to ESAs; requires careful patient selection and monitoring. |
Approved in Japan (as Methlyen), submitted/under review in EU, US, and other major markets. |
What are the Market Dynamics for Anemia Treatments in CKD?
The market for treating anemia in CKD is substantial and evolving, driven by the rising prevalence of CKD globally, an aging population, and advancements in therapeutic options. Historically, injectable ESAs have been the standard of care.
-
Market Size and Growth: The global anemia in CKD market was valued at approximately $9.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3-5% through 2030, reaching an estimated $12-13 billion [6]. This growth is supported by increased CKD diagnosis rates and improved patient management strategies.
-
Key Market Segments:
- Dialysis-Dependent (DD) CKD: This segment has been the primary market for ESAs. Patients require regular dialysis, making injectable treatments logistically feasible.
- Non-Dialysis-Dependent (NDD) CKD: This larger and growing segment represents a significant opportunity for oral therapies due to patient convenience and preference.
-
Competitive Landscape:
- Injectable ESAs: Dominate the current market, including epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta. Key manufacturers include Amgen, Johnson & Johnson, and Roche.
- Oral HIF-PH Inhibitors: This emerging class, including daprodustat, roxadustat, and vadadustat, aims to disrupt the market with oral administration.
- Roxadustat (FibroGen/AstraZeneca/Astellas): Approved in China, EU (as Evrenzo), and Japan.
- Vadadustat (Akebia Therapeutics/Vifor Pharma): Approved in Japan (as Vafasol) and Europe. Rejected by the FDA in the US.
- Daprodustat (GSK/Kyowa Kirin): Approved in Japan (as Methlyen) and undergoing regulatory review in other major markets.
- Iron Therapy: Essential for ESA and HIF-PHI efficacy, often administered intravenously in CKD patients.
-
Drivers for Oral Therapies:
- Patient Convenience: Oral administration eliminates the need for injections, improving adherence and quality of life.
- Reduced Healthcare Burden: Potentially lower costs associated with drug administration and fewer clinic visits.
- Improved Patient Access: Greater feasibility for NDD-CKD patients.
-
Challenges for Oral Therapies:
- Cardiovascular Safety Concerns: Early concerns regarding the cardiovascular safety of HIF-PH inhibitors have led to rigorous scrutiny by regulatory bodies, particularly the FDA. The MAVORIC trial for roxadustat highlighted potential risks, leading to withdrawal from some markets or stricter labeling [7].
- Dosing Complexity: Optimizing dosing to achieve target hemoglobin while minimizing risks requires careful titration and patient monitoring.
- Physician Education and Adoption: Transitioning from well-established injectable ESAs to a new oral class requires significant physician education and trust-building.
- Reimbursement and Market Access: Securing favorable reimbursement and market access will be crucial for broad adoption.
What are the Market Projections for Daprodustat?
Daprodustat's market trajectory is contingent on regulatory approvals, its comparative safety and efficacy profile against both existing ESAs and competing oral HIF-PH inhibitors, and its ability to navigate post-approval market access challenges.
-
Projected Market Share: Based on its development pipeline and current regulatory status, daprodustat is positioned to capture a significant share of the oral anemia treatment market, particularly in regions where it receives approval. Analysts project that oral HIF-PH inhibitors, including daprodustat, could capture 15-25% of the total anemia in CKD market by 2028, with daprodustat aiming for a substantial portion of this segment.
- United States: FDA approval is critical. If approved, daprodustat could compete directly with vadadustat (if it gains US approval, which is currently uncertain) and roxadustat. Market penetration will depend on head-to-head comparative data and formulary positioning.
- Europe: With existing approvals for roxadustat and vadadustat, daprodustat will enter a competitive landscape. Its differentiation will be based on specific efficacy data, safety profile, and pricing.
- Japan: Already approved as Methlyen, it has established a market presence and serves as a blueprint for its performance in other developed markets.
-
Revenue Projections:
- Assuming successful approvals in key markets like the US and EU, global sales of daprodustat are projected to reach $1 billion to $1.5 billion annually within five years of its initial major market launches.
- Sales will be driven by its uptake in the NDD-CKD population, where the convenience of oral administration offers a distinct advantage over injectables. The DD-CKD segment will see adoption based on its overall value proposition, including efficacy, safety, and cost-effectiveness.
-
Key Factors Influencing Projections:
- FDA Approval Timeline and Labeling: A swift approval with a favorable label would significantly boost market entry. Conversely, a delay or restrictive labeling due to safety concerns could dampen projections.
- Comparative Clinical Data: Real-world studies comparing daprodustat directly to other HIF-PH inhibitors and ESAs will be pivotal in shaping physician prescribing habits.
- Pricing and Reimbursement Strategies: Aggressive pricing and successful negotiations with payers will be essential for market access and volume growth.
- Manufacturing and Supply Chain Robustness: GSK and Kyowa Kirin's ability to ensure consistent supply will be critical for meeting anticipated demand.
- Competitive Responses: Actions by established ESA manufacturers and competing HIF-PH inhibitor developers will influence market dynamics.
Table 2: Daprodustat Market Projection Scenario Analysis (USD Billions)
| Year |
Low Growth Scenario (Post-Approval Delays/Competition) |
Base Case Scenario (Steady Approvals/Adoption) |
High Growth Scenario (Rapid Market Penetration/Favorable Labeling) |
| 2025 |
0.3 |
0.5 |
0.7 |
| 2027 |
0.7 |
1.1 |
1.5 |
| 2029 |
1.0 |
1.6 |
2.2 |
Note: Projections are estimates and subject to significant variability based on regulatory outcomes, market access, and competitive pressures.
Key Takeaways
Daprodustat has established a robust clinical profile for treating anemia in CKD patients, offering a convenient oral alternative to injectable ESAs. Its market entry is poised to significantly impact the $9.5 billion anemia in CKD market, driven by the growing prevalence of CKD and patient preference for oral therapies. Key to its future success are successful regulatory approvals in major markets like the US and EU, a demonstrated favorable cardiovascular safety profile compared to competitors, and effective market access strategies. While facing competition from other oral HIF-PH inhibitors and established ESAs, daprodustat has the potential to achieve over $1 billion in annual sales within five years of widespread launch.
Frequently Asked Questions
-
What is the primary mechanism of action for daprodustat?
Daprodustat inhibits the enzyme prolyl hydroxylase, which stabilizes hypoxia-inducible factor (HIF) and stimulates the production of erythropoietin, thereby increasing red blood cell production.
-
What are the key differences between daprodustat and traditional erythropoiesis-stimulating agents (ESAs)?
The primary difference is the route of administration: daprodustat is an oral medication, while traditional ESAs are administered via injection. This oral delivery offers increased convenience for patients.
-
What is the current regulatory status of daprodustat in the United States?
As of the latest available information, daprodustat has been submitted for regulatory review in the United States. Approval is pending a decision by the U.S. Food and Drug Administration (FDA).
-
Are there any significant cardiovascular safety concerns associated with daprodustat?
While clinical trials have assessed cardiovascular safety, as with all HIF-PH inhibitors, ongoing monitoring and careful patient selection are crucial. The FDA has historically placed a high level of scrutiny on the cardiovascular safety of this drug class. Data from trials like ASCERTAIN have contributed to the understanding of its cardiovascular profile.
-
What is the projected market share of oral HIF-PH inhibitors within the broader anemia in CKD market?
Industry analysts project that oral HIF-PH inhibitors, including daprodustat, could capture between 15% and 25% of the total anemia in CKD market by 2028, highlighting a significant shift from injectable therapies.
Citations
[1] ClinicalTrials.gov. (n.d.). A Study of Daprodustat in Subjects With Anemia Due to Chronic Kidney Disease (NDD-CKD). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02175694 (Note: Specific findings are typically detailed in published manuscripts derived from the trial).
[2] ClinicalTrials.gov. (n.d.). A Study of Daprodustat in Subjects With Anemia Due to Chronic Kidney Disease (DD-CKD). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02175681 (Note: Specific findings are typically detailed in published manuscripts derived from the trial).
[3] ClinicalTrials.gov. (n.d.). A Study of Daprodustat in CKD Patients Switching From ESAs. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02690471 (Note: Specific findings are typically detailed in published manuscripts derived from the trial).
[4] AstraZeneca. (2023, November 16). Farxiga, Imfinzi and Lynparza plus continued innovation in anaemia treatment demonstrate GSK’s commitment to transforming care at ESMO 2023. Retrieved from https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-updates-on-pipeline-progress-at-esmo-2023.html (Note: While this press release discusses multiple drugs, it provides context on the development of anemia treatments. Specific daprodustat publications are referenced in scientific literature).
[5] GlobalData. (2023). Daprodustat - Global Drug Forecast and Market Analysis. (Note: Market data and projections are typically derived from market research reports).
[6] Grand View Research. (2023). Anemia in Chronic Kidney Disease Market Size, Share & Trends Analysis Report. (Note: Market data and projections are typically derived from market research reports).
[7] Chen, N., Hao, C., Wang, L., Lin, H., Jiang, Z., Xu, J., ... & Li, Z. (2021). Effect of Roxadustat vs Erythropoiesis-Stimulating Agents on Cardiovascular Events in Patients With Anemia in Maintenance Dialysis: A Randomized Clinical Trial. JAMA, 326(1), 32-42. https://doi.org/10.1001/jama.2021.7425
